Table: Sawai Pharmaceutical -6-MTH group results (IFRS)

SAWAI group

09/11/2020 06:00

Nov 9 (Reuters)- 
              Sawai Pharmaceutical Co Ltd 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   6 months ended      6 months ended       Year to 
                  Sep 30, 2020        Sep 30, 2019     Mar 31, 2021 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales               90.17               90.48           200.20    
                   (-0.3 pct)          (+1.9 pct)       (+9.7 pct)  
  Operating           14.01               15.26            26.85    
                   (-8.1 pct)          (+10.8 pct)      (+0.2 pct)  
  Pretax              13.81               15.15            26.55    
                   (-8.8 pct)          (+10.7 pct)      (+0.2 pct)  
  Net                 10.80               10.97            20.05    
                   (-1.6 pct)          (+4.3 pct)       (+4.0 pct)  
  EPS Basic        246.65 yen          250.61 yen       457.85 yen  
  EPS Diluted      246.41 yen          250.42 yen                   
  Ann Div                              130.00 yen       130.00 yen  
  -Q2 Div           65.00 yen           65.00 yen                   
  -Q4 Div                               65.00 yen        65.00 yen  
 
  NOTE - Sawai Pharmaceutical Co Ltd. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4555.T